Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061449 · ClinicalTrials.gov registry record · Phase 1
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
A Phase 1 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02061449 is a Phase 1 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 3 participants.
The verdict
NCT02061449, a Phase 1 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study evaluates the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the histone deacetylase inhibitor (HDACI) Romidepsin.
Interventions
- DRUG Poly ICLC
- DRUG Romidepsin
- RADIATION Focal lesional radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-03 |
| Est. Completion | 2018-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02061449
The ClinicalTrials.gov registry entry for NCT02061449 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Poly ICLC is the first listed.
NCT02061449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02061449 about?
NCT02061449 is a clinical study titled "Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma". This study evaluates the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the histone deacetylase inhib...
What is the current status of trial NCT02061449?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-03. Estimated completion is 2018-11-05.
What interventions are being tested in trial NCT02061449?
The interventions under investigation include: Poly ICLC (DRUG), Romidepsin (DRUG), Focal lesional radiation (RADIATION).
Who is sponsoring clinical trial NCT02061449?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.